Abstract
The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.
Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders
Current Medicinal Chemistry
Title:Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors
Volume: 19 Issue: 21
Author(s): D. P. Zlotos
Affiliation:
Keywords: Melatonin, melatonin receptor agonists, melatonin receptor antagonists, melatonin receptor partial agonists, MT1 receptors, MT2 receptors, MT3 binding site, selective ligands, insomnia, sleep disorders
Abstract: The various physiological actions of the neurohormone melatonin are mediated mainly by two G-protein-coupled MT1 and MT2 receptors. The melatoninergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and PD-6735, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype selective MT1 and MT2 ligands. This review covers novel melatoninergic agonists and antagonists published since 2010, focusing on high-affinity and subtype selective agents. Additionally, compounds not mentioned in the previous review articles and ligands selective for the MT3 binding site are included.
Export Options
About this article
Cite this article as:
P. Zlotos D., Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors, Current Medicinal Chemistry 2012; 19 (21) . https://dx.doi.org/10.2174/092986712801323153
DOI https://dx.doi.org/10.2174/092986712801323153 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Coumarinyl Aryl/Alkyl Sulfonates with Dual Potential: Alkaline Phosphatase and ROS Inhibitory Activities: In-Silico Molecular Modeling and ADME Evaluation
Letters in Drug Design & Discovery Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science Tumor Immune Escape Mechanisms that Operate During Metastasis
Current Pharmaceutical Biotechnology Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Kv1.5 Blockers for the Treatment of Atrial Fibrillation: Approaches to Optimization of Potency and Selectivity and Translation to In Vivo Pharmacology
Current Topics in Medicinal Chemistry The Role of BMPs in Bone Anabolism and their Potential Targets SOST and DKK1
Current Molecular Pharmacology Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Discovery and Hit to Lead Optimization of Novel Combretastatin A-4 Analogues: Dependence of C-Linker Length and Hybridization
Anti-Cancer Agents in Medicinal Chemistry GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Aminoglycosidic Aminocyclitol Antibiotics-A Wonder, But Toxic Drugs:Developments and Clinical Implications
Anti-Infective Agents in Medicinal Chemistry